ClinicalTrials.Veeva

Menu
M

Marvel Clinical Research | Huntington Beach, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
Daridorexant
Dersimelagon
MT-7117
fezolinetant
ACT-541468
Tanezumab
Lorundrostat
Ritlecitinib
Dihydroergotamine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

21 of 47 total trials
Locations recently updated

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Active, not recruiting
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immun...

Active, not recruiting
Influenza
SARS-CoV-2
Biological: mRNA-1083.3
Biological: Influenza Vaccine 1

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Amlitelimab

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Enrolling
Non-segmental Vitiligo
Drug: Vehicle Gel
Drug: VYN201 Gel

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

The purpose of this study is to learn about the safety and effects of sisunatovir. Sisunatovir is studied for the possible treatment of Respiratory S...

Enrolling
Respiratory Syncytial Virus Infection
Drug: Placebo
Drug: Sisunatovir

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

To evaluate the long-term safety and tolerability of oral dersimelagon.

Active, not recruiting
EPP
XLP
Drug: MT-7117

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated...

Enrolling
X-Linked Protoporphyria (XLP)
Erythropoietic Protoporphyria (EPP)
Drug: Placebo
Drug: Dersimelagon

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: Placebo
Drug: AD109

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in...

Enrolling
Diabetes Mellitus, Type 1
Drug: Lispro
Drug: HDV-Lispro

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo

This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately...

Active, not recruiting
Influenza, Human
Biological: licensed QIV1
Biological: licensed QIV2

Trial sponsors

Pfizer logo
Incyte logo
Mitsubishi Tanabe Pharma logo
Moderna logo
AbbVie logo
Astellas logo
Idorsia Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
M
Seqirus logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems